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Background: Adherence to allergen immunotherapy is important for its effectiveness. There is currently limited data
available on allergen immunotherapy adherence outside of clinical trials i.e. in real-life clinical practice. As part of a European
Academy of Allergy and Clinical Immunology Immunotherapy Interest group initiative, we endeavoured to design a survey
in order to prospectively evaluate adherence to subcutaneous and sublingual immunotherapy across different European
countries.
Method/Design: The inclusion criteria for this prospective, multi-country survey were set as: adults, starting clinically
indicated allergen immunotherapy for respiratory allergic disorders or Hymenoptera venom allergy. An online survey was
designed in order to enrol participants and assess adherence to immunotherapy.
Eight countries (Czech Republic, Georgia, Germany, Greece, Italy, Poland, Portugal, Spain) were selected to reflect different
parts of Europe and differences in allergens and routes of immunotherapy administration. Each country has an allocated
National co-ordinator that has identified local Allergy departments willing to enrol participants in this survey.
Each participant will be followed up for a total of three years. In order to assess adherence, a 4-monthly follow-up form
detailing any missed doses and reasons will be completed online. In case of a participant discontinuing treatment, reasons
for this will be recorded.
Discussion: The use of online survey software has enabled us to make this survey a reality and reach clinicians in
different countries. Forty-five centres have enrolled a total of over 1,350 participants. It is hoped that this prospective
real life survey will enable us to gain a better understanding of reasons that affect adherence to subcutaneous and
sublingual immunotherapy and assist in developing ways to improve this.
Keywords: Adherence, Sublingual immunotherapy, Subcutaneous immunotherapy, Hymenoptera venom allergy,
Respiratory allergic disorders, Online survey, Online registerIntroduction
The lack of adherence to medication is an emerging and
worldwide problem in the treatment of chronic diseases.
It is responsible for a decrease of treatment efficacy, in-
creased hospitalisations, morbidity and mortality, and is
a significant burden for patients as well as for society
and healthcare systems [1]. Rates of treatment discon-
tinuation are reported to be between 20-40% for acute* Correspondence: melina.makatsori08@imperial.ac.uk
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unless otherwise stated.illnesses, increasing to 30-60% for chronic conditions and
reaching 80% in preventative interventions [2]. In the United
States alone, costs due to lack of adherence have reached
the figure of 100 billion dollars mainly due to unjustified
hospitalisations [3]. Accordingly, medical research has been
showing growing interest in this area. On PubMed, the
number of studies concerning this subject has more than
doubled within the last ten years, increasing from 1,349 in
2003 to 3,376 in 2013.
Adherence to treatment is the complex result of dif-
ferent determinants related to the patient, the disease,
the therapy, the patient/physician relationship and theral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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different ways in a single individual. Furthermore, the
complexity of the treatment schedule as well as the
route of administration can negatively affect adherence
[5,6].
Allergic rhinitis is a very common disease with a sig-
nificant socio-economic burden, due to direct (medica-
tions and doctor visits) and indirect costs (loss of
productivity/working days) [7]. Currently, the world-
wide prevalence of allergic rhinitis in adults ranges from
10-30%, but in children it reaches 37% in Western coun-
tries [7]. Discontinuation of pharmacological therapy is
a problem shared by allergic rhinitis as well as chronic
illnesses [6]. As far as allergen immunotherapy (AIT) is
concerned, adherence represents the most critical issue.
AIT significantly reduces the clinical symptoms at an
early stage as well as the use of concomitant medica-
tions, as reported by randomised controlled trials and
meta-analyses [7,8]. However, only after a long-term
course, whose recommended length is at least three years, it
is possible to obtain a long lasting effect following with-
drawal and to reduce the risk of development of asthma
and/or new sensitisations [9-16]. Immunotherapy for Hy-
menoptera venom allergy usually lasts between three and
five years. Adherence to this is thought to be higher given
the life-threatening reactions to venom, however this has
not been formally assessed [17].
Rates of adherence for individual patients are usually re-
ported as the percentage of the prescribed doses of the
medication actually taken by the patient over a specified
period. However, the evaluation of adherence is far from
standardised. In fact, many methods have been proposed to
measure adherence. Each of them has advantages and disad-
vantages but none of these can be currently considered the
gold standard [1]. Methods for assessing adherence to medi-
cation can generally be divided into three categories:
a) Subjective measurements based on what is reported
by the patient or caregiver. These methods, though
inexpensive, are not completely reliable, as patients
sometimes can deny the lack of regular medication
intake.
b) Objective assessment based on the count of pills
or the examination of pharmacy refill records.
The commonest drawback is that the absent pills
are considered actually taken by the patients. The
use of electronic devices can be more accurate,
but too costly in daily life.
c) Measurement of drug levels or drug metabolites in
serum or urine. The feasibility of this method is
limited to only a few drugs (such as digoxin, anti-
epileptics, theophylline, lithium). For asthmatic pa-
tients on regular oral steroids the evaluation of
serum cortisol can be helpful [6,18].Besides these technical limitations, a further methodo-
logical disadvantage is that if the patients are aware that ad-
herence is an outcome of the study a bias is immediately
introduced [1]. For this reason adherence data from rando-
mised controlled trials may not reflect a true representation
as participants are strictly followed and observed. More
consistent data are therefore likely to be collected from real
life studies.
In addition, the wide heterogeneity of immunotherapy
studies may account for the conflicting results and the diffi-
culty in drawing definite conclusions. Studies published so
far have been carried out in different populations, different
countries and according to different designs (retrospective,
cross sectional, prospective). Furthermore, patients were
treated with various allergen extracts and according to dif-
ferent schedules. Moreover, the methods used to measure
adherence were also dissimilar from study to study [19].
Interestingly, although an adherence rate is considered
generally acceptable when higher than 80%, a general
agreement on this cut off is still lacking [1,19].
Up to now, several studies have been published on sub-
cutaneous immunotherapy (SCIT) [20-34] as well as on sub-
lingual immunotherapy (SLIT) [35-46]. As shown in
Tables 1 and 2, the adherence rate is generally low and it
varies greatly for both SCIT and SLIT. Comparing the stud-
ies according to route of administration, a higher number of
SLIT studies reported an adequate (>80%) adherence. On
the other hand, SCIT studies included a larger population
and were of considerably longer duration.
Many reasons have been reported as being responsible
for immunotherapy discontinuation. Among the patient
related factors, a younger age and female gender appear to
be more frequently related to non adherence [21,25,32,42]
whereas severity of the disease seems not to affect the num-
ber of dropouts [27-41]. Among the causes for discontinu-
ation, treatment costs are relevant for both subcutaneous
and sublingual routes [21,23,26,31,34,37,38,40]. Local side
effects following administration may account for SLIT dis-
continuation in children as well in adults [37,38,40,45],
whereas inconvenience due to time consuming schedules,
or fear of injections are mainly related to SCIT treatments
[21,22,25]. In seasonal allergy, the use of cluster SCIT
schedules [20,22] as well as a pre-co-seasonal treatment
seem to favour a better adherence [39,40]. The overall ana-
lysis of these results does not appear to detect significant
differences in adherence according to delivery route [19],
but methodological and cultural heterogeneity of the stud-
ies currently do not allow for any firm conclusions.
Under the framework of the European Academy of
Allergy and Clinical Immunology (EAACI) Immuno-
therapy Interest Group, we endeavoured to design a sur-
vey in order to prospectively evaluate adherence to
subcutaneous and sublingual immunotherapy across
different European countries. This will include AIT for
Table 1 Adherence studies for SCIT
Author Study Population (pts) Age (A/C) Study duration Adherence rate (%)
Chon (1993) [20] 217 A 4 y 50
Lower (1993) [21] 315 C 4 y 56
Tinkelman (1993) [22] 3.349 C,A 1y 65
Ruiz (1997) [23] 247 A 18 m 62
Donahue (1999) [24] 603 C, A 4y 33
Rhodes (1999) [25] 1.033 A 3y 88
More & Hagan (2002) [26] 381 C,A 3y 77
Pajno (2005) [27] 1.886 C 3y 89
Hommers (2006) [28] 296 A not stated 66
Hankin (2008) [29] 520 C 3y 47 (1 y) 16 (3rd y)
Mahesh (2010) [30] 100 A not stated 58
Hsu & Reisacher (2012) [31] 139 A 4y 55
Guenechea (2013) [32] 156 A 5y 63
Kiel (2013) [33] 2.796 A 3y 23
Silva (2014) [34] 122 C, A 4y 54
A: adults, C: Children, Y: year, M: month.




The survey aims to assess adherence to AIT in a real life
setting. The primary objectives are to prospectively evalu-
ate the rate of adherence to AIT for inhalant allergies
(sublingual and subcutaneous routes) and Hymenoptera
venom allergy (subcutaneous) in a three year period inTable 2 Adherence studies in SLIT
Author Study population (pts)
Marogna (2004) [35] 319
Lombardi (2004) [36] 86
Pajno (2005) [27] 806
Passalacqua (2006) [37] 443
Passalacqua (2007) [38] 71
Cadario (2008) [39] 40
Roder (2008) [40] 154
Chang (2009) [41] 142
Jansen (2009) [42] 91
Ott (2009) [43] 183
Vita (2010) [44] 300
Pajno (2012) [45] 150
Hsu & Reisacher (2012) [31] 139
Kiel (2013) [33] 3.690
Trebuchon (2014) [46] 736
A: adults, C: Children, Y: year, M: month.real life across different European countries. The second-
ary objectives are to identify reasons for lack of adherence
and discontinuation of treatment and to explore possible
reasons for differences in adherence rates in different
countries and different individuals.
Survey design
This is a prospective, multi-centre, observational survey.
The survey will take place in eight countries: Czech Re-
public, Italy, Germany, Georgia, Greece, Poland, PortugalAge (A/C) Study duration Adherence rate (%)
A 3y 85
A 18 m 79-97
C 3y 79
A 6 m 76
C 6 m 85
A 1y 65
A 2y 77
A/C 6 m 69
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tive of different areas of Europe and also in order to in-
clude a variety of allergens contributing to allergic disease.
This is an online survey that will follow participants for
a period of 3 years from the start date of AIT. It was de-
cided to follow participants for a 3-year period as this is
the usual length of AIT treatment and there is concern
that adherence initially may be relatively good but this
may decrease as time passes.
Initially approval for this project was sought from the
EAACI Executive Committee. In order to initiate this
survey, the two PASTE survey co-ordinators and the
EAACI Immunotherapy Interest Group initially contacted
the National Allergy Societies of the eight countries to in-
form them about this survey. Each National Allergy Society
identified a "National survey Coordinator” that would be
responsible for coordinating all local activities in that coun-
try. This involved duties such as identifying study centres
willing to participate in the survey and dealing with na-
tional regulatory issues such as ethics and any other regula-
tory requirements.
In order for centres to be able to participate in the sur-
vey, they would need to have access to the internet and
have an allocated physician in charge who will be in con-
tact with the National survey Coordinator and who will
be able to complete the survey questionnaire in English.Figure 1 Study timeline.Participant selection and procedure
The survey population consists of adults with IgE mediated
respiratory allergies or Hymenoptera venom allergy who will
be starting AIT (either SCIT or SLIT) according to accepted
clinical standards of practice.
The inclusion criteria were set as: male or female, 18 years
of age or over (no upper age limit) and being eligible for im-
munotherapy to inhalant allergens or Hymenoptera venoms.
The exclusion criteria were previous AIT treatment at any
time and any contraindications to receiving immunotherapy
according to European standards of practice.
Each participating centre coordinator identified any
potential participants and assessed whether they met
these criteria. In order to enrol a participant, an online
enrolment questionnaire was required to be completed by
the physician. This form includes information about the
participant, details about their allergies and treatment.
For each participant an online follow up adherence form
will be completed by the local physician every 4 months.
This adherence follow-up form includes questions regard-
ing the number of missed doses, phase of the treatment at
the time and any possible reasons for missed doses. The
last adherence follow-up form will be completed at
36 months from AIT initiation.
In case of participant withdrawal, a discontinuation
online form will be completed. This includes questionsincluding the timing and any identified reasons for stop-
ping AIT.
The enrolment period opened in December 2012 and
closed in February 2014.
The study timeline is shown in Figure 1.
Questionnaire design
In order to identify the specific questions and areas to be in-
vestigated, the opinion and advice of experts in this field was
sought at an EAACI PASTE meeting in Geneva 2012. At
that stage, the content of the enrolment form, 4-monthly
follow up form and discontinuation form was agreed.
The enrolment includes information about age, sex, edu-
cation and employment status, allergen sensitisations, con-
dition for which receiving immunotherapy, allergen, route
and immunotherapy regime, date of AIT initiation, treat-
ment setting, follow-up arrangements as well as funding for
treatment.
For SCIT, recording of any missed doses is likely to be
more accurate as participants have to attend the clinic to
receive their injection and the physician is always aware of
any missed doses or discontinuation. Follow up of SLIT
patients varies in different countries and therefore a com-
promise was reached to enter follow-up data every
4 months as this would fit with the practice in some coun-
tries as well as not be a burden to the physicians who have
to complete these forms in their own time without any
specific funding. Depending on the practice of each coun-
try, other data such as pharmacy/prescription records,
follow-up appointments and telephone contact will be
used to improve patient reporting of any missed doses. It
was felt that use of other methods such as treatment diar-
ies may affect results by making patients more aware that
they are participating in an adherence survey and thus af-
fecting behaviours.
The follow up adherence form was designed to in-
clude questions regarding the number of missed doses
in the previous four months, the phase of the treatment
at the time i.e. up-dosing or maintenance and any
possible reasons for missed doses. Reasons investigated
included acute illness, forgetfulness, lack of efficacy,
Makatsori et al. Clinical and Translational Allergy  (2015) 5:17 Page 5 of 8financial costs, time/work commitments, local reaction,
systemic reaction, geographical constraints, new med-
ical condition/s, pregnancy and other.
The discontinuation form also explored specific rea-
sons for ending treatment.
The SurveyMonkey® online survey software was selected
to be used for the enrolment and follow up data collec-
tion. This allows participating centres to enter data from
different countries and enable collection in a central data-
base. All data entered is protected by an enhanced security
system (Secure Sockets Layer, SSL, a protocol for encrypt-
ing information over the Internet) [47].
The follow up survey forms used a skip logic pattern,
allowing participating clinicians to avoid certain sections
according to their responses in preceding questions.
The survey instruments were tested several times to en-
sure and improve their functionality and ease of use. At-
tention was also paid to user interface principles such as
colours selected, number of questions per screen, format-
ting of text and logical structure of the questionnaire.Data management
All data collected by the participating centres is entered
anonymously in a coded format in order to protect the
participants’ identity. A specific country code was allo-
cated to each country. An additional code beginning with
the country code was allocated to each centre of that spe-
cific country. Furthermore, each participant was given a
code incorporating both the country and centre code. This
way the enrolment forms can be matched with all the 4-
monthly follow up forms completed for each participant
at the stage of data analysis.
The data is regularly assessed by the survey co-ordinators
in order to check that it is being entered correctly.Data protection
In order to further protect the collected data, only the two
survey co-ordinators have access to the password pro-
tected completed questionnaires. In case of any queries or
mistakes made in the data entry, the survey co-ordinatorsTable 3 Different proportions of expected drop-out and confi








1000 60 600can be contacted to check the entered data and make any
necessary changes.
In addition, the SurveyMonkey® facility uses advanced
technology for Internet security. To use this tool, as ad-
ministrator, a unique user name and password must be
entered. SurveyMonkey® issues a session “cookie” only to
record encrypted authentication information for the dur-
ation of a specific session. Once the user accesses se-
cured areas, the Secure Sockets Layer (SSL) technology
protects user information using both server authentica-
tion and data encryption, ensuring that user data is safe,
secure, and available only to authorised persons. Survey-
Monkey® is PCI-DSS compliant [47].
Statistical analysis
Sample size estimation
Different proportions of expected drop-out are reported
in Table 3. Confidence intervals are computed under this
expected proportions assuming 1,000 patients will be
recruited.
Data analysis
The primary objective will be summarised as a propor-
tion ± confidence interval 95% (binomial method).
The influence of potential predictors on lack of adher-
ence or discontinuation from the therapy will be ex-
plored using a logistic regression. The effect of the
hierarchical structure of the data (participants nested in
centres nested in countries) on the results will be even-
tually explored using multilevel analyses.
Regulatory and ethical obligations
European Union and specific country ethics and regulatory
requirements, including data protection, will be followed.
Each National survey co-ordinator will be responsible for
addressing the corresponding ethics committee and local
regulatory requirements.
Survey progress
The PASTE co-ordinators are responsible for the proper
running of the survey. They are in regular contact withdence intervals
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quired. Meetings, conference calls and newsletters are used
as a method of updating progress. Following enrolment, the
next task is to ensure timely completion of the 4-monthly
follow up forms and any discontinuation forms for all the
enrolled participants. The data will then go through a fur-
ther clearing process, followed by data analysis.
Discussion
Adherence to AIT is an area that requires further investiga-
tion as the data currently available is mainly from clinical
trials with only a limited number of real life studies and
even fewer prospective studies [33,48-50].
This project will provide an insight into this important
issue. It will enable an estimation of the rate of adherence
to AIT in daily clinical practice for respiratory allergic dis-
orders and Hymenoptera venom allergy. Furthermore, it
will allow identification of possible reasons for lack of ad-
herence and discontinuation of treatment. This will provide
useful information for changing or modifying clinical be-
haviours and attitudes towards immunotherapy, in order to
improve adherence wherever possible.
The main strengths of this survey are:
1. As a multi-country survey a large number of partici-
pants will be recruited and adherence of AIT in a large
part of Europe will be assessed. Given the significant
number of participants included, the conclusions drawn
are more likely to be applicable to a wider population.
At the same time, it will enable identification of inter-
country differences regarding the use of different routes
of administration and reasons for discontinuation.
2. Sharing the same methodology by all participating
centres will allow for more reliable and comparable
results.
3. In addition to AIT for respiratory allergies,
adherence to Hymenoptera venom immunotherapy
will also be addressed in this survey. Possible
contributing factors leading to lack of adherence or
discontinuation will be explored in detail such as
extract used, schedule, responsible insect, severity of
index reaction and any side effects to AIT.
The use of online survey software has enabled us to
make this survey a reality and reach clinicians in 8 dif-
ferent countries. Following the end of the enrolment
period, over 1,350 participants have now been enrolled
by 45 centres. The main allergens for which participants
are having AIT include grass pollens 33.9%, house dust
mite 32.3% and 15.3% Hymenoptera venoms. Prelimin-
ary one-year follow up data shows that 11.1% of partici-
pants have missed on average 2 doses in 4 months
whilst less than 2% of participants have discontinued
treatment.Participants will be followed for a total of 3 years. At
that point we will be able to analyse all the data and dis-
seminate the findings to the allergy community in order
to benefit from this information and depending on the
outcomes consider targeting strategies and ways of im-
proving adherence.
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